Published On: Fri, Sep 16th, 2016

Anavex Life Sciences Corp. (AVXL) Stock Price Down 1.6%

Anavex Life Sciences Corp. (NASDAQ:AVXL) dropped 1.6% on Thursday . The stock traded as low as $2.45 and last traded at $2.51, with a volume of 289,701 shares traded. The stock had previously closed at $2.55.
A number of equities research analysts have commented on the stock. FBR & Co reissued an “outperform” rating and set a $10.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday, August 3rd. Maxim Group reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Monday, June 6th. Finally, Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, May 31st.
The stock’s market capitalization is $89.28 million. The firm’s 50-day moving average is $3.22 and its 200-day moving average is $4.69.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/15/anavex-life-sciences-corp-avxl-stock-price-down-1-6.html

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. Equities analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of AVXL. American International Group Inc. acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $115,000. Nationwide Fund Advisors acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $130,000. Squarepoint Ops LLC acquired a new position in shares of Anavex Life Sciences Corp. during the first quarter valued at about $107,000. Rhumbline Advisers acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $192,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Anavex Life Sciences Corp. during the second quarter valued at about $313,000. 10.72% of the stock is currently owned by hedge funds and other institutional investors.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>